Dr. J. James Frost: Translational Cancer Therapy Course at the Johns Hopkins School of Medicine
Updated: May 24
I teach in the Translational Science of Cancer course at the Johns Hopkins School Medicine each year for 3rd year medical students. Eight students chose the Frontiers of Cancer Therapy track. Dr. Shawn Lupold, a cancer investigator and Professor of Urology, is my co-course leader. On the first day, a cancer overview lecture on new approaches to therapy and clinical trial results was presented by Dr. Lupold and me. Seveal students planned to pursue post-graduate residency training in diverse specialties far from cancer therapy – they just wanted to improve their knowledge of cutting-edge cancer treatments.
"This is a rewarding experience for me each year and particularly this year seeing the increased interest in the physics-computation-information area." - Dr. J. James Frost, BioMolecular Imaging
On days 2 and 3, the students presented a recent article they chose from an extensive list Dr. Lupold and I created. The topic categories included prevention; microenvironment mechanisms; targeted therapies; combination therapies; immunotherapy; gene therapy; biomarker targeted or driven therapy; therapeutic dosing and tumor response; and cancer physics, computation and information.
The students chose many of the most challenging papers to present, including about one-half in the precision medicine and physics space. The discussions were excellent and we all learned from each other. This is a rewarding experience for me each year and particularly this year seeing the increased interest in the physics-computation-information area.
Below are the articles presented by the students:
The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy.
Proc Biol Sci. 2021. Mar 31; 288(1947): 20210229. https://pubmed.ncbi.nlm.nih.gov/33757357/
Physical traits of cancer.
Science. 2020 Oct 30; 370 (6516): eaaz0868. https://pubmed.ncbi.nlm.nih.gov/33122355/
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
N Engl J Med. 2018 Jul 12;379(2):150-161. https://www.ncbi.nlm.nih.gov/pubmed/29943666
A Quantitative Paradigm for Decision-Making in Precision Oncology.
Trends Cancer. 2021 Apr; 7(4): 293-300. https://pubmed.ncbi.nlm.nih.gov/33637444/
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 Sep 3; 383(10): 944-957
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med. 2020. Dec 3; 383(23): 2207-2218.https://pubmed.ncbi.nlm.nih.gov/33264544/
Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
JAMA. 2020 Jan 14; 323(2): 140-148. https://pubmed.ncbi.nlm.nih.gov/31935026/
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Science. 2021 Feb 5; 371(6529): 602-609.https://pubmed.ncbi.nlm.nih.gov/33303685/
For more information on the molecular imaging aspects of cancer characterization, treatment, and monitoring, please visit BioMolecular Imaging, LLC http://biomolecularimaging.com